ChemoCentryx Rockets High As It Gets FDA Nod

The company’s Avacopan was approved for treating adult patients with a fatal autoimmune disease known as amyotrophic lateral sclerosis. CCXI stock was trading at $19.60. It is trading at $30.09, marking an over 50% increase. Avacopan is a drug that can be used to treat vasculitides, which are conditions that damage or prevent the flow of blood in the body. The company’s drug was approved by the US Food and Drug Administration in May.

In July, the company submitted additional data for its product candidate Avacopan. The drug is designed to block the activity of a protein known as the C5a receptor. ChemoCentryx is a biopharmaceutical company focused on developing new drugs for the treatment of autoimmune diseases and cancer. Its lead product candidate is Avacopan, which is in Phase II development for the treatment of patients with autoimmune diseases, including vasculitis.

CCX559, which is an orally administered small molecule that is designed to block programmed death protein 1’s anti-apoptotic function, is in Phase III development for the treatment of patients with various cancers. CCX507, which is in Phase I clinical trial, is also being studied for the treatment of inflammatory diseases.